Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Enliven Therapeutics. The associated price target remains the same with $39.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sam Slutsky has given his Buy rating due to a combination of factors that highlight Enliven Therapeutics’ favorable positioning in chronic myeloid leukemia (CML). He points to the latest Phase 1b results for ELVN-001, which show robust major molecular response and deep molecular response rates across the 60, 80, and 120 mg once-daily cohorts, with responses appearing durable and consistent. The absence of a clear dose–response penalty on safety or efficacy within this range supports flexibility in dose selection for later-stage trials. Slutsky also emphasizes that these updated data, based on higher and more representative doses, better reflect the true competitive profile of ELVN-001 versus other emerging CML therapies.
In addition, he notes the company’s clear path forward, including plans to deliver further Phase 1 data from the ENABLE trial around mid-2026 and to initiate a pivotal second-line and later study in the second half of 2026. When compared with a key competitor program such as TERN-701, Slutsky views ELVN-001’s profile as compelling within the evolving CML treatment landscape. He also factors in Enliven’s multi-year cash runway, which reduces near-term financing risk and supports the advancement of its clinical program. Taken together, the strength of the clinical data, the strategic development timeline, and the company’s financial position underpin his Buy recommendation on ELVN shares.